Microbiota and metabolites modulation of cancer stem cells and chemotherapy sensitivity
Listen to this summary
This review explores how the microbiota and its metabolites influence cancer stem cells (CSCs) and their role in chemotherapy resistance. The authors aim to elucidate the mechanisms by which commensal microbes and their metabolites affect CSC function and the tumor microenvironment, while also discussing potential therapeutic strategies to target these interactions to enhance chemosensitivity and improve patient outcomes.
This is one of 33,000+ journals available on OSLR. Try it free for 14 days.
Free 14-day trial. 33,000+ journals. Cancel anytime.
More from Gut
View all →Jun 23, 2026 · Gut
Pancreatic cancer fibrosis activates protumorigenic Schwann cells through a nuclear mechanosensing mechanism
Jun 22, 2026 · Gut
Functional anti-preS1 antibody responses associated with viral control in chronic hepatitis B
Jun 17, 2026 · Gut
Course and clinical outcomes of chronic hepatitis delta: a longitudinal analysis of 565 patients from the D-SOLVE and HDV-1000 consortia
Jun 17, 2026 · Gut
Use of genetic analysis in adult cholestatic liver disease: lessons from progressive paediatric syndromes and cohort studies
Jun 17, 2026 · Gut
Combined acetaldehyde metabolism burden modifies IBD susceptibility to alcohol consumption
Jun 12, 2026 · Gut
SPP1<sup>+</sup> macrophages facilitate the differentiation and maturation of regulatory T cells in tumour-draining lymph nodes of colorectal cancer
More in Internal Medicine
View all →Jun 25, 2026 · Blood
Combining Quizartinib with intensive chemotherapy in older patients with newly diagnosed AML: results of the UK NCRI AML18 Trial
Jun 25, 2026 · Blood
Translational Regulation of Sf1 Integrates Alternative Splicing and Hematopoietic Stem Cell Fate
Jun 25, 2026 · Blood
Galectin-1 Fuels Monocyte Hyperinflammation and Represents a Novel Therapeutic Target in Myeloproliferative Neoplasms
Jun 25, 2026 · The American journal of sports medicine
Association of Central Acetabular Osteophytes With Microinstability and Increased Combined Anteversion in Borderline Dysplasia Hips
Jun 25, 2026 · Blood
NG2-ITGA4 axis regulates Rho GTPases and leukemic aggressiveness in KMT2A-r B-ALL and is targetable with natalizumab
Jun 24, 2026 · Lancet (London, England)
Safety, pharmacokinetics, and exploratory efficacy of the oral ghrelin receptor agonist AC01 in heart failure with reduced ejection fraction (GOAL-HF1): a randomised, double-blind, placebo-controlled, phase 1b/2a study
"Oslr has become part of my weekly routine on my day off. The clinical relevance of the summaries is outstanding — I'd rate it 9/10. Being able to consume research hands-free is a huge advantage for busy physicians."
Dr. Jennifer Thompson
Portland, OR
Stay current without falling behind
33,000+ journals. 3-minute audio summaries. Free for 14 days.
